Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-10-02
1999-03-23
Wilson, James O.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 42, 514 43, 514 46, 514 47, 514 48, 514 49, 514 50, 514 51, 536 41, 536 172, 536 173, 536 181, 536 184, 536 2723, 536 276, 536 278, 536 2781, 536 281, 536 2853, 536 2854, A61K 3170
Patent
active
058859721
ABSTRACT:
This invention relates to .alpha. and .beta.-L-pyranosyl nucleosides of Formula (I), wherein the nucleoside substitution on the pyranosyl carbohydrate molecule comprises a substituted or unsubstituted purine (adenine or guanine) or pyrimidine (cytosine, uracil, thymine and hypoxanthine) base. Also provided are methods to make the .alpha. and .beta.-L-pyranosyl nucleosides and methods of using such to treat cancer in a mammal.
REFERENCES:
patent: 3457255 (1969-07-01), Jones et al.
patent: 3817982 (1974-06-01), Verheyden et al.
patent: 4340729 (1982-07-01), D'Souza et al.
patent: 4659698 (1987-04-01), Imbach et al.
patent: 4880782 (1989-11-01), Eckstein et al.
patent: 4918056 (1990-04-01), Bobek et al.
L.M. Lerner et al. (1987) Journal of Medicinal Chemistry 30(8):1521-1525.
L. Novotny et al. (1994) Collection of Czechoslovak Chemical Communications 59(7)1691-1698.
K.A. Watanabe et al. (1974) Journal of Organic Chemistry 39(17)2482-2486.
H. Aoyama, Bull. Chem. Soc. Jpn., 60:2073-2077 (1987).
M. Asai, et al., Chem. Pharm. Bull., 15(12), 1863-1870 (1967).
U. Asseline, et al., Nucleic Acids Research, vol. 19, No. 15, 4067-4074 (1991).
M.V. Baud, et al., Tetrahedon Letters, vol. 31, 4437-4440 (1990).
A. Bloch, et al., J. Med. Chem., vol. 10, No. 5, 908-912 (1967).
G. Etzold, et al., Chem. Ber., 101:226-234 (1968).
V. Fucik, et al., Nucleic Acids Research, vol. 1, No. 4,639-644, Apr. 1974.
S. Fujimori, et al., Nucleosides & Nucleotides, 11(2-4), 341-349 (1992).
C. Genu-Dellac, et al., Nucleocides & Nucleotides, 10(6), 1345-1376 (1991).
C. Genu-Dellac, et al., Antiviral Chem. & Chemother. 2(2), 83-92 (1991).
C. Genu-Dellac, et al., Tet. Letters, vol. 32, No. 1, 79-82 (1991).
G. Gosselin, et al., Antmicrob. Agents Chemother., vol. 38, No. 6, 1292-1297, Jun. 1994.
J.G. Gu, et al., J. Neurochemistry, vol. 56, 548-552 (1991).
A. Holy, Nucleic Acid Chemistry, Part 1, 347-353, Eds. L.B. Townsend and R.S. Tipson, Wiley & Sons, New York (1978).
A. Holy, et al., Biol. Chem. Hoppe-Seyler, 366:355-359, Apr. 1985.
A. Holy, Nucleic Acid Chemistry, vol. 2, 527-532 (1978).
A. Holy, et al., Coll. Czech. Chem. Commun., vol. 34 (1969).
M. Jurovcik, et al., Febs Letters, vol. 18, No. 2, 274-276 (1971).
A.M. Kritzyn, et al., Coll. Czech. Chem. Commun., vol. 40, 3211-3219 (1975).
P. Langen, et al., Progress in Antimicrobial and Anticancer Chemotherapy, Proceedings of the 6th International Congress of Chemotherapy, University Park Press, England, 1970, vol. II, 394-397.
K.F. Lau, et al., Cancer Chemotherapy Reports, Part II, vol. 3,95-109 (1972).
L.M. Lerner, Preparation of Nucleosides, vol. 34, No. 1, 101-103 (1969).
M. Miwa, et al., Chem. Pharm. Bull., 38(4), 998-1003 (1990).
D.H. Murray, et al., J. Phar. Sci., vol. 56, No. 7, 865-870 (1967).
N. Nagasawa, et al., J. Org. Chem., 32:251-252 (1967).
C. Perigaud, et al., Nucleosides & Nucleotides, 11(2-4), 903-945 (1992).
S. Savithiry, et al., Physiol. Plant., 84:460-466 (1992).
B. Schwarz, et al., Coll. Czech. Chem. Commun. 45:3217-3230 (1980).
B. Shimizu, et al., Chem. Pharm. Bull., 15(12):2011-2014 (1967).
B. Shimizu, et al., Nucleic Acid Chemisrty, vol. 2, 783-792 (1978).
S. Spadari, J. Med. Chem., 35:4214-4220 (1992).
R.A. Taube, et al., Biochimica et Biophysica Acta, 255:6-18 (1972).
I. Votruba, et al., Febs Letters, vol. 19, No. 2, 136-138 (1971).
M.A. Waqar, et al., J. Cell. Physiol., 121:402-408 (1984).
A.F. Wu, et al., Biochemistry, 63:1222-1226 (1969).
Arteaga et al., Cancer Research, vol. 47, pp. 6248-6253, (1987).
Scheithaver et al., Cancer Research, vol. 46, pp. 2703-2708, (1986).
Hanauske et al., Selective Cancer Therapeutics, vol. 5, No. 3, pp. 97-111, (1989).
Goodhue Charles T.
Weis Alexander L.
Genencor International Inc.
Glaister Debra J.
Wilson James O.
LandOfFree
L-pyranosyl nucleosides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with L-pyranosyl nucleosides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and L-pyranosyl nucleosides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2125527